HR+/HER2- EARLY BREAST CANCER
Clinical trials for HR+/HER2- EARLY BREAST CANCER explained in plain language.
Never miss a new study
Get alerted when new HR+/HER2- EARLY BREAST CANCER trials appear
Sign up with your email to follow new studies for HR+/HER2- EARLY BREAST CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New study tracks Ribociclib's Real-World impact on early breast cancer in saudi arabia
Disease control Recruiting nowThis study is observing about 177 people in Saudi Arabia with HR+/HER2- early breast cancer who are already taking ribociclib plus hormone therapy as part of their routine care. Researchers will track how long patients stay free from cancer returning and note any side effects. Th…
Matched conditions: HR+/HER2- EARLY BREAST CANCER
Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated May 26, 2026 10:49 UTC
-
Breast cancer study checks if patients stay on treatment
Knowledge-focused Recruiting nowThis study looks at how often patients with high-risk early breast cancer keep taking the drug abemaciclib after 6 months. Researchers will review past treatment records from 200 women to see how many stay on therapy. The goal is to understand real-world adherence, not to test a …
Matched conditions: HR+/HER2- EARLY BREAST CANCER
Sponsor: Institut fuer Frauengesundheit • Aim: Knowledge-focused
Last updated May 22, 2026 13:53 UTC